[
  {
    "id": "ch22_q01",
    "text": "Correct HIV progression?",
    "options": [
      "Acute->AIDS",
      "Viral transmission -> Seroconversion -> Acute -> Chronic -> AIDS",
      "AIDS first",
      "Transmission->AIDS"
    ],
    "correctIndex": 1,
    "rationale": "Transmission > Antibodies > Acute Sx > Latency > AIDS."
  },
  {
    "id": "ch22_q02",
    "text": "Sign of deterioration in HIV?",
    "options": [
      "Undetectable load",
      "Weight loss >10%",
      "Night sweats",
      "CD4 600"
    ],
    "correctIndex": 1,
    "rationale": "Wasting syndrome (>10% loss) indicates progression."
  },
  {
    "id": "ch22_q03",
    "text": "PrEP is:",
    "options": [
      "Vaccine",
      "Daily med to prevent HIV",
      "After sex",
      "Cure"
    ],
    "correctIndex": 1,
    "rationale": "Pre-Exposure Prophylaxis prevents acquisition."
  },
  {
    "id": "ch22_q04",
    "text": "CD4 count of 180 indicates:",
    "options": [
      "Acute HIV",
      "AIDS",
      "Adherence",
      "Normal"
    ],
    "correctIndex": 1,
    "rationale": "AIDS < 200 CD4 cells."
  },
  {
    "id": "ch22_q05",
    "text": "Opportunistic Infection (OI) in AIDS?",
    "options": [
      "Strep",
      "PCP Pneumonia",
      "Flu",
      "Eczema"
    ],
    "correctIndex": 1,
    "rationale": "PCP is a classic OI."
  },
  {
    "id": "ch22_q06",
    "text": "Goal of ART?",
    "options": [
      "Cure",
      "Undetectable viral load",
      "Increase virus",
      "Decrease CD4"
    ],
    "correctIndex": 1,
    "rationale": "Suppress virus to undetectable levels."
  },
  {
    "id": "ch22_q07",
    "text": "Kaposi",
    "options": [
      "Purple/red skin lesions",
      "White patches",
      "Diarrhea",
      "Blindness"
    ],
    "correctIndex": 0,
    "rationale": "Cancer of blood vessels causing purple lesions."
  },
  {
    "id": "ch22_q08",
    "text": "Needle stick priority?",
    "options": [
      "Wait",
      "PEP within 72h",
      "Antibiotics",
      "Retire"
    ],
    "correctIndex": 1,
    "rationale": "Post-Exposure Prophylaxis ASAP (max 72h)."
  },
  {
    "id": "ch22_q09",
    "text": "Undetectable viral load means:",
    "options": [
      "Cured",
      "Gone",
      "Untransmittable (U=U)",
      "Stop meds"
    ],
    "correctIndex": 2,
    "rationale": "Cannot transmit sexually, but must keep taking meds."
  },
  {
    "id": "ch22_q10",
    "text": "Oral Thrush presents as:",
    "options": [
      "Blisters",
      "Creamy white patches",
      "Bleeding",
      "Taste loss"
    ],
    "correctIndex": 1,
    "rationale": "Fungal infection, white patches."
  },
  {
    "id": "ch22_q11",
    "text": "HIV Screening/Confirmation test?",
    "options": [
      "CBC",
      "CXR",
      "4th Gen Antigen/Antibody",
      "UA"
    ],
    "correctIndex": 2,
    "rationale": "Detects p24 antigen and antibodies early."
  },
  {
    "id": "ch22_q12",
    "text": "IRIS is:",
    "options": [
      "Collapse",
      "Immune recovery causing inflammation",
      "Stop meds",
      "Mutation"
    ],
    "correctIndex": 1,
    "rationale": "Recovering immune system attacks old infections."
  },
  {
    "id": "ch22_q13",
    "text": "Vertical Transmission:",
    "options": [
      "Sex",
      "Needles",
      "Mother-to-child",
      "Blood"
    ],
    "correctIndex": 2,
    "rationale": "Perinatal transmission."
  },
  {
    "id": "ch22_q14",
    "text": "ART Adherence requirement:",
    "options": [
      "When sick",
      "95%+",
      "Double dose",
      "Stop if side effects"
    ],
    "correctIndex": 1,
    "rationale": "Strict adherence prevents resistance."
  },
  {
    "id": "ch22_q15",
    "text": "TB in HIV:",
    "options": [
      "Rare",
      "Leading cause of death",
      "Untreatable",
      "No isolation"
    ],
    "correctIndex": 1,
    "rationale": "Major coinfection and killer."
  },
  {
    "id": "ch22_q16",
    "text": "Window period for HIV testing refers to:",
    "options": [
      "Treatment duration",
      "Time between infection and detectable antibodies",
      "CD4 recovery time",
      "Viral load doubling time"
    ],
    "correctIndex": 1,
    "rationale": "It takes 2-12 weeks for antibodies to develop; tests may be negative during this time."
  },
  {
    "id": "ch22_q17",
    "text": "Common side effect of Efavirenz (NNRTI)?",
    "options": [
      "Weight gain",
      "Vivid dreams/CNS effects",
      "Hair loss",
      "Diarrhea"
    ],
    "correctIndex": 1,
    "rationale": "Efavirenz commonly causes neuropsychiatric side effects including vivid dreams."
  },
  {
    "id": "ch22_q18",
    "text": "PrEP (Pre-Exposure Prophylaxis) is for:",
    "options": [
      "Treating HIV infection",
      "Preventing HIV in high-risk individuals",
      "Curing AIDS",
      "Treating opportunistic infections"
    ],
    "correctIndex": 1,
    "rationale": "PrEP (Truvada/Descovy) reduces HIV acquisition risk by >90% when taken consistently."
  },
  {
    "id": "ch22_q19",
    "text": "CD4 count indicating severe immunosuppression/AIDS?",
    "options": [
      ">500",
      "350-500",
      "200-350",
      "<200"
    ],
    "correctIndex": 3,
    "rationale": "CD4 <200 defines AIDS and dramatically increases opportunistic infection risk."
  },
  {
    "id": "ch22_q20",
    "text": "Cryptococcal meningitis in AIDS patients presents with:",
    "options": [
      "Rash",
      "Severe headache & altered mental status",
      "Cough",
      "Diarrhea"
    ],
    "correctIndex": 1,
    "rationale": "Fungal meningitis causes headache, fever, and neurological changes."
  },
  {
    "id": "ch22_q21",
    "text": "Adherence requirement for ART effectiveness?",
    "options": [
      "50%",
      "75%",
      ">95%",
      "Take when sick"
    ],
    "correctIndex": 2,
    "rationale": "Strict adherence >95% prevents resistance and maintains viral suppression."
  },
  {
    "id": "ch22_q22",
    "text": "Wasting syndrome (HIV-associated) is defined as:",
    "options": [
      "Weight gain",
      ">10% unintentional weight loss",
      "Increased muscle mass",
      "Fluid retention"
    ],
    "correctIndex": 1,
    "rationale": "AIDS wasting involves severe involuntary weight loss with muscle depletion."
  },
  {
    "id": "ch22_q23",
    "text": "Integrase inhibitor example?",
    "options": [
      "Raltegravir",
      "Efavirenz",
      "Lamivudine",
      "Ritonavir"
    ],
    "correctIndex": 0,
    "rationale": "Raltegravir (Isentress) blocks HIV integration into host DNA."
  },
  {
    "id": "ch22_q24",
    "text": "Patient education about ART resistance?",
    "options": [
      "Missing doses has no effect",
      "Resistance develops with inconsistent use",
      "Double dose if missed",
      "Stop meds if feeling better"
    ],
    "correctIndex": 1,
    "rationale": "Inconsistent dosing allows viral replication and mutation to resistant strains."
  },
  {
    "id": "ch22_q25",
    "text": "Legal requirement for HIV status disclosure?",
    "options": [
      "Must tell everyone",
      "Varies by state; often required to inform sexual partners",
      "Never required",
      "Only employers need to know"
    ],
    "correctIndex": 1,
    "rationale": "Laws vary; many states criminalize non-disclosure to sexual partners."
  }
]